Ablynx is a clinical-stage biopharmaceutical company dedicated to creating new medicines which will make a real difference to society.

The Company has more than 45 proprietary and partnered product candidates in development for the treatment of a wide range of diseases, including inflammation, haematology, respiratory disease, immuno-oncology and oncology. Eight Nanobodies are currently in clinical development and the first potential product (caplacizumab for the treatment of acquired TTP) launch is expected in 2018.